Psychiatric News
April 13, 2020
Nick Zagorski
Back to table of contents Previous article Next article Clinical & ResearchFull AccessPsychedelics for Psychiatric Disorders: More Research NeededNick ZagorskiNick ZagorskiSearch for more papers by this authorPublished Online:13 Apr 2020https://doi.org/10.1176/appi.pn.2020.4a14AbstractAPA’s Work Group on Biomarkers and Novel Treatments suggests that psychedelic drug trials need more standard...
April 6, 2020
Maria Dell’Isola
2 citations
Both the historiographical analysis and the ancient documents about the Christian movement known as Montanism place paramount importance on prophecy, visions, and ecstasy. The theological refutation of Montanist teaching and doctrine in the heresiological sources was almost entirely shaped by the attribution of deceitfulness and error to the experience of ecstatic prophecy. Even though some...
Psychiatric News
March 20, 2020
Katie O’connor
Though the field is young, psychedelics appear to hold promise as a treatment for addiction, even as barriers to research persist. Researchers around the world are investigating how drugs such as LSD, MDMA (also known as ecstasy), ketamine, and psilocybin (the active ingredient in magic mushrooms) can treat patients with substance use disorders (SUD). Though there is still a lot to learn, early...
Frontiers in Neuroscience
February 26, 2020
Monika Kacela, Piotr Adamowicz, Jolanta B. Zawilska
79 citations
Recently, a new class of psychedelic compounds named NBOMe (or 25X-NBOMe) has appeared on the illegal drug market. NBOMes are analogs of the 2C family of phenethylamine drugs, originally synthesized by Alexander Shulgin, that contain a N-(2-methoxy)benzyl substituent. The most frequently reported drugs from this group are 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe. NBOMe compounds are ultrapotent and...
Journal of the Neurological Sciences
January 31, 2020
Tingying Chi, Jessica A. Gold
95 citations
Though there was initial interest in the use of psychedelic drugs for psychiatric treatment, bad outcomes and subsequent passage of the Substance Act of 1970, which placed psychedelic drugs in the Schedule I category, significantly limited potential progress. More recently, however, there has been renewal in interest and promise of psychedelic research. The purpose of this review is to...
Frontiers in Psychiatry
January 22, 2020
Earth Erowid, Fire Erowid, Albert Garcia‐romeu et al.
155 citations
While these cross-sectional and self-report methods cannot determine whether psychedelics caused changes in drug use, results suggest the potential that psychedelics cause reductions in problematic substance use, and support additional clinical research on psychedelic-assisted treatment for SUD.
European Addiction Research
2020
Franz Moggi, Deborah Schorno, Leila M. Soravia et al.
22 citations
<b><i>Background:</i></b> Attention deficit/hyperactivity disorder (ADHD), conduct disorder (CD), and sensation seeking (SS) have been consistently related to a higher risk of substance use (SU) and substance use disorder (SUD). <b><i>Objectives:</i></b> To investigate the relationship between ADHD and prevalence rates in males at age 20 and age 25, the initiation of SU and SUD after age 20,...
Drug Science, Policy and Law
2020
Natasha L. Mason, Patrick C. Dolder, Kim P. C. Kuypers
15 citations
Background It has been suggested that the outcome of the psychedelic experience is dependent on set and setting. While scientific research into the therapeutic potential of psychedelics is growing, it is clear that in clinical populations an optimal set and setting will not always be attainable. It was aimed to assess under which emotional and environmental circumstances psychedelic users use...
Psychiatric News
October 28, 2019
Nick Zagorski
1 citation
A total of $17 million in private donations to the Hopkins center is expected to provide five years of operational funding for the center’s researchers and staff. The center will also train graduate students. With the aid of $17 million in private funds, Johns Hopkins University has launched a center to explore the potential of psychedelic compounds such as psilocybin (magic mushrooms) and...
Health SA Gesondheid
September 18, 2019
Annelize Vorster, Anthonie M. Gerber, Lynette J. van der Merwe et al.
21 citations
Background: Health professional students frequently use alcohol and narcotics. The potential impact on academic performance and professional behaviour is concerning.Aim: This study aimed to determine self-reported use of alcohol, illicit substances (e.g. cannabis, lysergic acid diethylamide [LSD], magic mushroom, cocaine, crack, ecstasy, methamphetamine and heroin), prescription medication and...